Our results also revealed that PRMT5 deficiency in tumor cells increased the percentage and the number of CD4+ T and CD8+ T cells, which is consistent with an earlier report of the role of PRMT5 in melanoma 37. This evidence concerns the gene CD8A and neoplasm.